Drugs / DC-CIK
DC-CIK
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07343791 | Nov 2025 → Nov 2027 expected | colorectal cancer | JIANG LONGWEI | Recruiting | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT05622825 | Jan 2023 → Dec 2024 | liver cancer | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03393858 | Dec 2017 → Dec 2021 | malignant mesothelioma | Capital Medical University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02425748 | Jun → Dec 2017 | lung cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT03047525 | Feb 2017 → Jan 2019 | colorectal cancer, lung cancer, nasopharyngeal carcinoma, renal cell carcinoma | Xiaoyi Huang | Unknown | No outcome recorded |
| Phase 1/2 | NCT03360630 | Nov 2016 → Dec 2022 | lung cancer | Capital Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT02418481 | Apr 2015 → Jun 2016 | breast cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT01781520 | Jun 2013 → May 2016 | malignant pancreatic neoplasm | Capital Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT01783951 | Feb 2013 → Feb 2018 | gastric cancer | Capital Medical University | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02491697 | Feb 2016 → Aug 2030 expected | breast cancer | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02644863 | Dec 2015 → Dec 2018 | esophageal cancer | Shenzhen Hornetcorn Bio-technology Company, LTD | Unknown | No outcome recorded |
| Phase 2 | NCT02487017 | May 2015 → Dec 2018 | hepatocellular carcinoma | Shenzhen Hornetcorn Bio-technology Company, LTD | Unknown | No outcome recorded |
| Phase 2 | NCT02202928 | Jul 2014 → Dec 2017 | colorectal cancer | Shenzhen Hornetcorn Bio-technology Company, LTD | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02415699 | Aug 2015 → Jul 2017 | colorectal cancer | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02851784 | Dec 2009 → Dec 2028 expected | hepatocellular carcinoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04214717 | Dec 2019 → Dec 2023 | cancer | Yantai Yuhuangding Hospital | Unknown | No outcome recorded |
| — | NCT03158480 | Jun 2017 → Dec 2018 | anogenital human papillomavirus infection | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04292769 Background | Jan 2020 → Jan 2023 | cancer | Li Yu | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC-CIK | “Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment” NCT03047525 ↗17“DC-CIK and CTL were administered intraperitoneally” NCT02851784 ↗ |
| Known as | D-CIK | “Antigen-sensitized DC-CIK 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16,...” NCT02644863 ↗ |
| Known as | Dendritic and Cytokine-induced Killer Cells | “Combinations of Dendritic and Cytokine-induced Killer Cells (DC-CIK) and Cytokine-induced Killer Cells (CIK) treatment may enhance the immune response and stop cancer cells...” NCT03047525 ↗ |
| Modality | Cell therapy | “cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.” NCT01781520 ↗ |
| Route | Intravenous | “IV (in the vein)” NCT02202928 ↗ |